Singular Genomics Systems, Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 2, 2022

Rhea-AI Summary

Singular Genomics Systems, Inc. will report its fourth quarter and full year 2021 financial results on March 2, 2022, after market close. Management will host a conference call at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The company focuses on next-generation sequencing and multiomics technologies, enhancing research and clinical capabilities. Their foundational product, the Singular Sequencing Engine, underpins two key developments: the G4 for NGS and the PX, integrating single cell and spatial analysis with genomics and proteomics.

Positive

• Launch of G4 product targeting NGS market.
• Development of PX for integrated multiomics solutions.

Negative

• None.

LA JOLLA, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc., a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the fourth quarter and full year 2021 after the market close on Wednesday, March 2, 2022. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at investor.singulargenomics.com, in the News & Events section.

About Singular Genomics Systems, Inc.
Singular Genomics is a life science technology company that is leveraging novel, next generation sequencing (NGS) and multiomics technologies to build products that empower researchers and clinicians. Our mission is to accelerate genomics for the advancement of science and medicine. Our Singular Sequencing Engine is the foundational platform technology that forms the basis of our products as well as our core product tenets: power, speed, flexibility, and accuracy. We are currently developing two products that are purpose built to target applications in which these core product tenets matter most. Our first product, the G4, targets the NGS market. Our second product in development, the PX, combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument to offer a versatile multiomics solution.

Investor Contact
Matt Clawson
949-370-8500
ir@singulargenomics.com

Media Contact
Dan Budwick, 1AB
973-271-6085
dan@1abmedia.com

FAQ

When will Singular Genomics report its Q4 and full year 2021 financial results?

Singular Genomics will report its financial results on March 2, 2022.

What products is Singular Genomics currently developing?

The company is developing the G4 for the NGS market and the PX for multiomics solutions.

What time is the conference call for Singular Genomics' financial results?

The conference call will begin at 1:30 p.m. PT/4:30 p.m. ET.

Where can I listen to the Singular Genomics conference call?

The conference call can be accessed via a live and archived webcast at their investor relations website.